首页 | 本学科首页   官方微博 | 高级检索  
检索        

静脉血栓栓塞症患者活化蛋白C抗性及凝血因子V活性和基因多态性研究
引用本文:韩轩茂,任景芳,郝斌,曹文东,刘秀娥,侯丽虹,郭志萍,于斌,王学峰,丁秋兰,杨林花.静脉血栓栓塞症患者活化蛋白C抗性及凝血因子V活性和基因多态性研究[J].中国实验血液学杂志,2007,15(3):612-616.
作者姓名:韩轩茂  任景芳  郝斌  曹文东  刘秀娥  侯丽虹  郭志萍  于斌  王学峰  丁秋兰  杨林花
作者单位:1. 山西医科大学第二医院血液科,太原030001
2. 山西医科大学第二医院血管外科,太原030001
3. 上海交通大学瑞金医院输血科,上海200050
基金项目:山西省留学回国人员科研启动基金
摘    要:本研究旨在观察静脉血栓栓塞患者凝血因子V(Factor V,F V)活性改变,检测活化蛋白C抗性(activated protein C resistance,APCR)和凝血因子V基因F V Leiden、F V Cambridge、F V Hong Kong、F V Asp79His和F V I359T多态性.对95例静脉血栓栓塞患者(其中下肢深静脉血栓79例,肺栓塞4例,下肢深静脉血栓合并肺栓塞12例)和95例正常对照者.应用限制性内切酶片段长度多态性测定FV Leiden、F V Cambridge和F V Hong Kong多态性,用MassARRAYTM技术检测F V Asp79His、F V I359T多态性.以一期法和校正的APTT试验分别对其中的65例静脉血栓栓塞患者和60例正常对照者行凝血因子V活性水平和活化蛋白C抵抗检测.结果表明静脉血栓栓塞患者血浆凝血因子V活性水平(108.03%±28.29%)高于对照组(95.17%±29.75%),差异有显著性统计学意义(P=0.008);静脉血栓栓塞组活化蛋白C抵抗阳性13例(20.0%),对照组3例(5.0%),二组比较,有统计学意义(P=0.012).二组均未发现FV Leiden、F V Cambridge、F V Hong Kong、FV Asp79His和FV I359T多态性.结论凝血因子V活性升高和活化蛋白C抵抗是静脉血栓栓塞的危险因素,但APCR与F V Leiden、F V Cambridge、F V HongKong、F V Asp79His和F V I359T多态性无关.

关 键 词:静脉血栓栓塞  活化蛋白C抵抗  凝血因子V  基因多态性
文章编号:1009-2137(2007)03-0612-05
修稿时间:2006年6月19日

Analysis of Activated Protein C Resistance,Factor V Coagulation Activity and Gene Polymorphisms in Patients with Venous Thromboembolism
HAN Xuan-Mao,REN Jin-Fang,HAO Bin,CAO Wen-Dong,LIU Xiu-E,HOU Li-Hong,GUO Zhi-Ping,YU Bin,WANG Xue-Feng,DING Qiu-Lan,YANG Lin-Hua.Analysis of Activated Protein C Resistance,Factor V Coagulation Activity and Gene Polymorphisms in Patients with Venous Thromboembolism[J].Journal of Experimental Hematology,2007,15(3):612-616.
Authors:HAN Xuan-Mao  REN Jin-Fang  HAO Bin  CAO Wen-Dong  LIU Xiu-E  HOU Li-Hong  GUO Zhi-Ping  YU Bin  WANG Xue-Feng  DING Qiu-Lan  YANG Lin-Hua
Institution:1.Department of Hematology, 2. Department of Angiosurgery , The Second Hospital, Shanxi Medical University, Taiyuan 030001, China; 3. Department of Blood Transfusion, Ruijin Hospital, Shanghai Jiaotong University, Shanghai 200050, China
Abstract:The study was aimed to investigate the factor V coagulation activity (FV:C), and to evaluate FVgene polymorphisms and activated protein C resistance (APCR) in the patients with venous thromboembolism (VTE). 95 patients with VTE and 95 normal controls were investigated for FV gene polymorphisms. FV Leiden, FVCambridge, and FVHong Kong were detected by PCR, MnlI and BstNI digestion respectively. FVAsp79His and FVI359T were detected by MassARRAY. FV:C and APCR in 65 patients with VTE and 60 normal controls were determined by a one-stage clotting method and the APTT-based assays respectively. The results showed that the mean levels of plasma FV:C were significantly higher in VTE group than that in controls (108.03% +/- 28.29% vs 95.17% +/- 29.75%) (P = 0.008), the incidence of APCR were 20.0% (13 of 65 cases) in patients with VTE and 5.0% (3 of 60 cases) in normal controls (P = 0.012). FV Leiden, FVCambridge, FVHong Kong, FVAsp79His and FVI359T mutations were not found in two groups. It is concluded that the increased plasma level of FV:C is a risk factor for VTE. There is APCR in both groups, APCR is also a risk factor to VTE. APCR may not be associated with mutations of FV Leiden, FVCambridge, FVHong Kong, FVAsp79His and FV I359T polymorphisms, other factors need to study further in APCR.
Keywords:venous thromboembolism  activated protein C resistance  factor V coagulation activity  gene polymorphisms
本文献已被 CNKI 维普 万方数据 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号